CASE CCC IN THE NEWS
5 Questions...With Celebrated Pediatric Oncologist Peter de Blank
The Daily - Aug 15, 2014
The Daily interviews pediatric oncologist and Case Comprehensive Cancer Center member Peter de Blank, MD.
Oncology Hospitalists: An Emerging and Growing Specialty
Medscape - Aug 15, 2014
As a medical specialty, the number of hospitalists, along with the number of institutions using hospitalists, has grown rapidly since the mid-1990s. There were about 11,000 hospitalists working in the United States in 2003, according to a Society of Hospital Medicine (SHM) estimate, and about 35,000 in 2012..."Our program started with 1 oncologist – me," said Jonathan Wynbrandt, MD, who leads the oncology hospitalist program at University Hospitals Case Medical Center in Cleveland. "Oncologists were spending more time in the clinic and less time with hospitalized patients, so we thought that this would be better for continuity of care." When the program began in 2010, Dr. Wynbrandt evaluated the needs of inpatients. "We went ahead and recruited 2 more doctors to join me the following year," he said.
Cleveland Clinic Plans $276 Million Cancer Center
Crain's Business Cleveland- Aug 15, 2014
Cleveland Clinic on Thursday, Aug. 14, announced plans to build a massive, $276 million cancer facility, which will unite much of the cancer care currently scattered around the Clinic's sprawling campus east of downtown Cleveland. The 377,000-square-foot, seven-story facility will be north of Carnegie Avenue between East 102nd and East 105th streets adjacent to the Crile building. The Clinic said it expects to break ground on the facility Sept. 29 and hopes to have it complete in early 2017. Funding for the facility is expected to come from the $2 billion fundraising campaign the Clinic went public with earlier this summer. "Cancer patients are uniformly scared," said Dr. Brian J. Bolwell, chairman of the Clinic's Taussig Cancer Institute, in an interview with Crain's. "We have to provide many different ways to help patients and their families deal with medical aspect of their disease but also the psychological aspect. Having a central location to do both – provide multidisciplinary care and support services – is very, very important."
CWRU, UH Researchers' Discovery Behind First Approved Stool DNA Colorectal Cancer Screening Test
The Plain Dealer - Aug 13, 2014
The Food and Drug Administration this week approved the first stool-based colorectal screening test approved for the detection of colorectal cancer and precancerous growths that can be used in the privacy of one's home. The technology used to create the test emerged more than a decade ago from labs at University Hospitals Case Medical Center and Case Western Reserve University...Cologuard is a second-generation successor to ColoSure, a stool DNA, or sDNA test, that Exact Sciences developed with UH and CWRU researchers. In 2003, Dr. Sanford Markowitz, professor of cancer genetics at CWRU School of Medicine, member of the Case Comprehensive Cancer Center, and an oncologist at UH Seidman Cancer Center, led a team that helped develop the technology behind the stool DNA test. They discovered a specific DNA change that takes place in colorectal cancers. They then created techniques for detecting the DNA change when it was expelled from the body in feces.
Pittsburgh-based Study Offers Hope for Early Esophageal Cancer Test
Pittsburgh Post-Gazette - Aug 5, 2014
Having found a way to address the disease's genetic diversity, Pittsburgh-based researchers published a study Tuesday offering hope of a simple blood test for early detection of lethal esophageal cancer...The researchers identified four proteins associated with the onset of esophageal cancer, described as a rapidly increasing and particularly deadly disease. Identification of the biomarker panel is a precursor to developing a blood test for early detection and better treatment...Research into blood-based biomarkers for cancer is "the search for the Holy Grail," and the Pittsburgh study is a "landmark," said Charis Eng, founding director of the Genomic Medicine Institute at Cleveland Clinic's Lerner Research Institute and member of the Case Comprehensive Cancer Center.
CORE FACILITY SPOTLIGHT
Gene Expression & Genotyping Facility
When a team of researchers at the Case Comprehensive Cancer Center wanted to study the link between genetic variants and the risk of developing colon cancer, they relied on the expertise of the Gene Expression & Genotyping Facility (GEGF) and its director, Marty Veigl, PhD, Associate Professor of General Medical Sciences (Oncology).
Recent studies identified 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel colon cancer suppressor, which means that loss of the gene function could result in an increased risk of colon cancer. A team of researchers led by Li Li, MD, PhD, Associate Director for Prevention Research at the Case CCC and Professor of Family Medicine at the CWRU SOM, hoped to build upon these findings to determine whether 15-PGDH is a colon cancer susceptibility gene, and if it plays a role in colon cancer carcinogenesis in the general population.
Researchers Dr. Li and Sandy Markowitz, MD, PhD, Co-Leader of the Case CCC Cancer Genetics Program and Markowitz-Ingalls Professor of Cancer Genetics at the CWRU SOM, partnered with the GEGF to design a three-stage study where they identified a genetic variant, then tested it in a validation population. In this study, the GEGF played a critical scientific role in designing the genetic study, identifying single nucleotide polymorphisms, and completing all of the genetic analyses. Specifically, the GEGF performed TaqMan assays to genotype PGDH for 102 SNPs in colon cancer cases and controls.
Steve Fink, PhD, Instructor in the Division of Hematology/Oncology at the CWRU SOM, working with Dr. Markowitz, assessed changes in expression of the PGDH gene in a subset of the colon cancer patients that were genotyped by the GEGF. Review of the genotyping data by Cheryl Thompson, PhD, Assistant Professor in the CWRU SOM Department of Family Medicine, and Robert Elston, PhD, Professor of Epidemiology & Biostatistics at CWRU, identified an allele associated with increased risk of colon cancer. This data further suggested that carriers of this risk allele exhibit decreased expression of 15-PGDH in the colon.
In addition to the important findings of this study, two additional projects stemmed from this research. Dr. Li used these findings as preliminary data to obtain a four-year U01 from the National Cancer Institute to search for more biomarkers, and to determine whether additional genetic polymorphisms in the 15-PGDH pathway are linked to susceptibility to early colon neoplasia. Dr. Veigl and the GEGF staff will again lead the genotyping and the expression analyses for this project.
Study co-authors Drs. Markowitz and Fink have also extended this observation and partnered with researchers at Harvard University to examine material from two long-term studies involving nearly 128,000 participants. This work discovered that aspirin can reduce colorectal cancer risks for those with high levels of 15-PGDH. The findings were reported in a high profile publication and received a great deal of media attention.
Citation: Thompson CL, Fink SP, Lutterbaugh JD, Elston RC, Veigl ML, Markowitz, SD and Li L. (2013) Genetic Variation in 15-Hydroxyprostaglandin Dehydrogenase and Colon Cancer Susceptibility. PLoS ONE 8(5): e64122.doi:10.1371/journal.pone.0064122.
Prevent Cancer Foundation 2014 Research Grant and Fellowship Program
The Prevent Cancer Foundation is accepting applications for the following opportunities. Proposals must fall within the scope of the Foundation's mission and funding priorities to be considered. The goal of the Foundation's research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources.
- 2014 Fellowships: Awards are limited to postdoctoral level applicants ONLY. Therefore, only graduate students who will have their doctoral degree before the project start date are eligible to apply. Postdoctoral researchers from non-profit institutions (including academic institutions) are eligible to apply. Researchers from for-profit institutions will not be considered.
Deadline: August 27
- 2014 Grants: are open to early career researchers at the instructor or assistant professor level; more senior researchers who have shifted their area of interest toward primary and secondary cancer prevention; researchers at any academic level who need seed funding to test an innovative hypothesis; and researchers from non-profit institutions (including academic institutions) are eligible to apply. Researchers from for-profit institutions will not be considered.
Deadline: August 27
NIH BULLETIN – Notices and Funding Opportunities
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.